Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains

Cancer Research
Hongzhuang PengF J Rauscher

Abstract

Deleterious mutations of the ubiquitin carboxy-terminal hydrolase BAP1 found in cancers are predicted to encode inactive truncated proteins, suggesting that loss of enzyme function is a primary tumorigenic mechanism. However, many tumors exhibit missense mutations or in-frame deletions or insertions, often outside the functionally critical UCH domain in this tumor suppressor protein. Thus, precisely how these mutations inactivate BAP1 is unknown. Here, we show how these mutations affect BAP1 interactions with the Polycomb group-like protein, ASXL2, using combinations of computational modeling technology, molecular biology, and in vitro reconstitution biochemistry. We found that the BAP1-ASXL2 interaction is direct and high affinity, occurring through the ASXH domain of ASXL2, an obligate partner for BAP1 enzymatic activity. The ASXH domain was the minimal domain for binding the BAP1 ULD domain, and mutations on the surfaces of predicted helices of ASXH abolished BAP1 association and stimulation of BAP1 enzymatic activity. The BAP1-UCH, BAP1-ULD, and ASXH domains formed a cooperative stable ternary complex required for deubiquitination. We defined four classes of alterations in BAP1 outside the UCH domain, each failing to produc...Continue Reading

References

Apr 5, 2000·The Journal of Biological Chemistry·H PengF J Rauscher
Jun 1, 2006·Proteins·Arun S KonagurthuArthur M Lesk
Aug 25, 2007·Genetics·Andrés Gaytán de Ayala AlonsoJürg Müller
Sep 12, 2007·Bioinformatics·M A LarkinD G Higgins
Jan 2, 2009·Cancer Research·Hiroyuki NishikawaTomohiko Ohta
Apr 29, 2009·Journal of Computational Chemistry·Garrett M MorrisArthur J Olson
Sep 29, 2009·Nature·Mark A DawsonTony Kouzarides
Oct 24, 2009·The Journal of Biological Chemistry·Hongzhuang PengFrank J Rauscher
May 4, 2010·Nature·Johanna C ScheuermannJürg Müller
Nov 6, 2010·Science·J William HarbourAnne M Bowcock
Jun 28, 2011·Nature Genetics·Alexander HoischenBert B B A de Vries
Aug 30, 2011·Nature Genetics·Joseph R TestaMichele Carbone
Aug 30, 2011·Nature Genetics·Thomas WiesnerMichael R Speicher
Sep 24, 2011·Journal of Medical Genetics·Mohamed H Abdel-RahmanFrederick H Davidorf
Sep 29, 2011·Proteins·Sethe E BurgieGeorge N Phillips
Aug 11, 2012·Science·Anwesha DeyVishva M Dixit
Apr 4, 2013·Nature Reviews. Cancer·Michele CarboneGiovanni Gaudino
Mar 19, 2014·Current Opinion in Structural Biology·Tomonao Inobe, Andreas Matouschek
Dec 29, 2016·Current Medical Research and Opinion·Juliana Alvarez Argote, Constantin A Dasanu

❮ Previous
Next ❯

Citations

Jun 5, 2019·Future Oncology·Vincenzo Di NunnoFrancesco Massari
Aug 21, 2018·Stem Cells International·Yu-Chen GuoQuan Yuan
Dec 6, 2018·Journal of the National Cancer Institute·Sebastian WalpoleNicholas K Hayward
Aug 1, 2018·High-throughput·Adam P SageWan L Lam
Aug 14, 2020·Cell Chemical Biology·Julie M Garlick, Anna K Mapp
Sep 30, 2019·Progress in Retinal and Eye Research·Kyra N SmitEmine Kiliҫ

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.